Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Seeks Pediatric Review Of Four Cancer Drugs With Hard-to-study Populations

This article was originally published in The Pink Sheet Daily

Executive Summary

ODAC's pediatric subcommittee will consider pediatric development plans and the formulation of written requests for Allos' Folotyn, Amgen's Prolia, Eisai's eribulin and Pfizer's crizotinib.

You may also be interested in...

Absence Of Pediatric Plans Put NDAs/BLAs At Risk For Refusal To File

FDA may refuse to file drug applications that do not include a pediatric plan when sponsors ask for a deferral of pediatric data until after a drug is approved.

Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern

Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.

FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow

Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts